The Experts below are selected from a list of 3102 Experts worldwide ranked by ideXlab platform

John M Moriarty - One of the best experts on this subject based on the ideXlab platform.

Sammy Saab - One of the best experts on this subject based on the ideXlab platform.

  • coil assisted retrograde transvenous obliteration CARTO an alternative treatment option for refractory hepatic encephalopathy
    The American Journal of Gastroenterology, 2018
    Co-Authors: Sammy Saab, Savannah Fletcher, Francisco Durazo, Justin P Mcwilliams, Joseph Dinorcia, Ronald W. Busuttil, Fady M Kaldas, Siddharth A Padia
    Abstract:

    Overt hepatic encephalopathy (OHE) is a serious complication of liver dysfunction, which is associated with severe morbidity/mortality and healthcare resource utilization. OHE can be medically refractory due to spontaneous portosystemic shunts (SPSSs) and therefore a new treatment option for these SPSSs is critical. This is a retrospective study of 43 patients with medically refractory OHE, who underwent CARTO (Coil-Assisted Retrograde Transvenous Obliteration) procedures between June 2012 and October 2016. The patient demographic characteristics, technical and clinical outcomes with an emphasis on HE improvement, and complications are reviewed and analyzed. The overall clinical success rate was 91% with a significant HE improvement. Eighty-one percent of patients had clinically significant improvement from OHE and 67% of patients had complete resolution of their HE symptoms during our follow-up period of 893 ± 585 days (range 36–1881 days, median 755.0 days). The median WH score improved from 3 (range 2–4) pre-CARTO to 1 (range 0–4) post-CARTO (p < 0.001). The median ammonia level significantly decreased from 134.5 pre-CARTO to 70.0 post-CARTO (p < 0.001) in 3 days. The overall mean survival was 1465.5 days (95% CI of 1243.0 and 1688.0 days). Only three patients had recurrent HE symptoms. There were 39.6% minor complication rate including new or worsened ascites and esophageal varices, and only 2.3% major complication rate requiring additional treatment (one patient with bleeding esophageal varices requiring treatment). No procedure-related death is noted. CARTO appears to be a safe and effective treatment option for refractory overt hepatic encephalopathy (OHE) due to spontaneous portosystemic shunts. CARTO could be an excellent addition to currently available treatment options for these patients.

  • coil assisted retrograde transvenous obliteration CARTO for the treatment of portal hypertensive variceal bleeding preliminary results
    Clinical and translational gastroenterology, 2014
    Co-Authors: Edward Lee, Francisco Durazo, Justin P Mcwilliams, Ronald W. Busuttil, Sammy Saab, Antoinette S Gomes, Stevenhuy B Han, Leonard I Goldstein, Bashir A Tafti, John M Moriarty
    Abstract:

    Coil-Assisted Retrograde Transvenous Obliteration (CARTO) for the Treatment of Portal Hypertensive Variceal Bleeding: Preliminary Results

Ronald W. Busuttil - One of the best experts on this subject based on the ideXlab platform.

  • coil assisted retrograde transvenous obliteration CARTO an alternative treatment option for refractory hepatic encephalopathy
    The American Journal of Gastroenterology, 2018
    Co-Authors: Sammy Saab, Savannah Fletcher, Francisco Durazo, Justin P Mcwilliams, Joseph Dinorcia, Ronald W. Busuttil, Fady M Kaldas, Siddharth A Padia
    Abstract:

    Overt hepatic encephalopathy (OHE) is a serious complication of liver dysfunction, which is associated with severe morbidity/mortality and healthcare resource utilization. OHE can be medically refractory due to spontaneous portosystemic shunts (SPSSs) and therefore a new treatment option for these SPSSs is critical. This is a retrospective study of 43 patients with medically refractory OHE, who underwent CARTO (Coil-Assisted Retrograde Transvenous Obliteration) procedures between June 2012 and October 2016. The patient demographic characteristics, technical and clinical outcomes with an emphasis on HE improvement, and complications are reviewed and analyzed. The overall clinical success rate was 91% with a significant HE improvement. Eighty-one percent of patients had clinically significant improvement from OHE and 67% of patients had complete resolution of their HE symptoms during our follow-up period of 893 ± 585 days (range 36–1881 days, median 755.0 days). The median WH score improved from 3 (range 2–4) pre-CARTO to 1 (range 0–4) post-CARTO (p < 0.001). The median ammonia level significantly decreased from 134.5 pre-CARTO to 70.0 post-CARTO (p < 0.001) in 3 days. The overall mean survival was 1465.5 days (95% CI of 1243.0 and 1688.0 days). Only three patients had recurrent HE symptoms. There were 39.6% minor complication rate including new or worsened ascites and esophageal varices, and only 2.3% major complication rate requiring additional treatment (one patient with bleeding esophageal varices requiring treatment). No procedure-related death is noted. CARTO appears to be a safe and effective treatment option for refractory overt hepatic encephalopathy (OHE) due to spontaneous portosystemic shunts. CARTO could be an excellent addition to currently available treatment options for these patients.

  • coil assisted retrograde transvenous obliteration CARTO for the treatment of portal hypertensive variceal bleeding preliminary results
    Clinical and translational gastroenterology, 2014
    Co-Authors: Edward Lee, Francisco Durazo, Justin P Mcwilliams, Ronald W. Busuttil, Sammy Saab, Antoinette S Gomes, Stevenhuy B Han, Leonard I Goldstein, Bashir A Tafti, John M Moriarty
    Abstract:

    Coil-Assisted Retrograde Transvenous Obliteration (CARTO) for the Treatment of Portal Hypertensive Variceal Bleeding: Preliminary Results

Francisco Durazo - One of the best experts on this subject based on the ideXlab platform.

  • coil assisted retrograde transvenous obliteration CARTO an alternative treatment option for refractory hepatic encephalopathy
    The American Journal of Gastroenterology, 2018
    Co-Authors: Sammy Saab, Savannah Fletcher, Francisco Durazo, Justin P Mcwilliams, Joseph Dinorcia, Ronald W. Busuttil, Fady M Kaldas, Siddharth A Padia
    Abstract:

    Overt hepatic encephalopathy (OHE) is a serious complication of liver dysfunction, which is associated with severe morbidity/mortality and healthcare resource utilization. OHE can be medically refractory due to spontaneous portosystemic shunts (SPSSs) and therefore a new treatment option for these SPSSs is critical. This is a retrospective study of 43 patients with medically refractory OHE, who underwent CARTO (Coil-Assisted Retrograde Transvenous Obliteration) procedures between June 2012 and October 2016. The patient demographic characteristics, technical and clinical outcomes with an emphasis on HE improvement, and complications are reviewed and analyzed. The overall clinical success rate was 91% with a significant HE improvement. Eighty-one percent of patients had clinically significant improvement from OHE and 67% of patients had complete resolution of their HE symptoms during our follow-up period of 893 ± 585 days (range 36–1881 days, median 755.0 days). The median WH score improved from 3 (range 2–4) pre-CARTO to 1 (range 0–4) post-CARTO (p < 0.001). The median ammonia level significantly decreased from 134.5 pre-CARTO to 70.0 post-CARTO (p < 0.001) in 3 days. The overall mean survival was 1465.5 days (95% CI of 1243.0 and 1688.0 days). Only three patients had recurrent HE symptoms. There were 39.6% minor complication rate including new or worsened ascites and esophageal varices, and only 2.3% major complication rate requiring additional treatment (one patient with bleeding esophageal varices requiring treatment). No procedure-related death is noted. CARTO appears to be a safe and effective treatment option for refractory overt hepatic encephalopathy (OHE) due to spontaneous portosystemic shunts. CARTO could be an excellent addition to currently available treatment options for these patients.

  • coil assisted retrograde transvenous obliteration CARTO for the treatment of portal hypertensive variceal bleeding preliminary results
    Clinical and translational gastroenterology, 2014
    Co-Authors: Edward Lee, Francisco Durazo, Justin P Mcwilliams, Ronald W. Busuttil, Sammy Saab, Antoinette S Gomes, Stevenhuy B Han, Leonard I Goldstein, Bashir A Tafti, John M Moriarty
    Abstract:

    Coil-Assisted Retrograde Transvenous Obliteration (CARTO) for the Treatment of Portal Hypertensive Variceal Bleeding: Preliminary Results

Justin P Mcwilliams - One of the best experts on this subject based on the ideXlab platform.

  • coil assisted retrograde transvenous obliteration CARTO an alternative treatment option for refractory hepatic encephalopathy
    The American Journal of Gastroenterology, 2018
    Co-Authors: Sammy Saab, Savannah Fletcher, Francisco Durazo, Justin P Mcwilliams, Joseph Dinorcia, Ronald W. Busuttil, Fady M Kaldas, Siddharth A Padia
    Abstract:

    Overt hepatic encephalopathy (OHE) is a serious complication of liver dysfunction, which is associated with severe morbidity/mortality and healthcare resource utilization. OHE can be medically refractory due to spontaneous portosystemic shunts (SPSSs) and therefore a new treatment option for these SPSSs is critical. This is a retrospective study of 43 patients with medically refractory OHE, who underwent CARTO (Coil-Assisted Retrograde Transvenous Obliteration) procedures between June 2012 and October 2016. The patient demographic characteristics, technical and clinical outcomes with an emphasis on HE improvement, and complications are reviewed and analyzed. The overall clinical success rate was 91% with a significant HE improvement. Eighty-one percent of patients had clinically significant improvement from OHE and 67% of patients had complete resolution of their HE symptoms during our follow-up period of 893 ± 585 days (range 36–1881 days, median 755.0 days). The median WH score improved from 3 (range 2–4) pre-CARTO to 1 (range 0–4) post-CARTO (p < 0.001). The median ammonia level significantly decreased from 134.5 pre-CARTO to 70.0 post-CARTO (p < 0.001) in 3 days. The overall mean survival was 1465.5 days (95% CI of 1243.0 and 1688.0 days). Only three patients had recurrent HE symptoms. There were 39.6% minor complication rate including new or worsened ascites and esophageal varices, and only 2.3% major complication rate requiring additional treatment (one patient with bleeding esophageal varices requiring treatment). No procedure-related death is noted. CARTO appears to be a safe and effective treatment option for refractory overt hepatic encephalopathy (OHE) due to spontaneous portosystemic shunts. CARTO could be an excellent addition to currently available treatment options for these patients.

  • coil assisted retrograde transvenous obliteration CARTO for the treatment of portal hypertensive variceal bleeding preliminary results
    Clinical and translational gastroenterology, 2014
    Co-Authors: Edward Lee, Francisco Durazo, Justin P Mcwilliams, Ronald W. Busuttil, Sammy Saab, Antoinette S Gomes, Stevenhuy B Han, Leonard I Goldstein, Bashir A Tafti, John M Moriarty
    Abstract:

    Coil-Assisted Retrograde Transvenous Obliteration (CARTO) for the Treatment of Portal Hypertensive Variceal Bleeding: Preliminary Results